Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
43.1M
-
Number of holders
-
49
-
Total 13F shares, excl. options
-
27.8M
-
Shares change
-
-1.76M
-
Total reported value, excl. options
-
$38.6M
-
Value change
-
-$1.38M
-
Put/Call ratio
-
0
-
Number of buys
-
15
-
Number of sells
-
-21
-
Price
-
$1.39
Significant Holders of Repare Therapeutics Inc. - Common Shares, no par value (RPTX) as of Q2 2025
64 filings reported holding RPTX - Repare Therapeutics Inc. - Common Shares, no par value as of Q2 2025.
Repare Therapeutics Inc. - Common Shares, no par value (RPTX) has 49 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 27.8M shares
of 43.1M outstanding shares and own 64.45% of the company stock.
Largest 10 shareholders include BVF INC/IL (10.3M shares), Blue Owl Capital Holdings LP (3.44M shares), ORBIMED ADVISORS LLC (3.32M shares), Versant Venture Management, LLC (2.65M shares), Redmile Group, LLC (1.59M shares), MPM ASSET MANAGEMENT LLC (1.12M shares), CITADEL ADVISORS LLC (937K shares), MPM BIOIMPACT LLC (820K shares), ACADIAN ASSET MANAGEMENT LLC (681K shares), and RENAISSANCE TECHNOLOGIES LLC (523K shares).
This table shows the top 49 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.